apixaban Side Effects
Also known as: Eliquis
Analysis of 62,650 adverse event reports submitted to the FDA from 2005 to 2025.
Total Reports
62,650
Death-Related
6,759
10.8% of reports
Hospitalizations
27,509
43.9% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 6,759 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 2,331 |
| PNEUMONIA | 296 |
| FALL | 280 |
| ACUTE KIDNEY INJURY | 276 |
| DYSPNOEA | 268 |
| CEREBRAL HAEMORRHAGE | 262 |
| CARDIAC FAILURE | 247 |
| OFF LABEL USE | 247 |
| CARDIAC ARREST | 214 |
| ANAEMIA | 192 |
| COMPLETED SUICIDE | 190 |
| SEPSIS | 188 |
| SEPTIC SHOCK | 188 |
| GASTROINTESTINAL HAEMORRHAGE | 176 |
| HAEMORRHAGE INTRACRANIAL | 172 |
| HYPOTENSION | 170 |
| TOXICITY TO VARIOUS AGENTS | 161 |
| RESPIRATORY FAILURE | 148 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 147 |
| CEREBROVASCULAR ACCIDENT | 140 |
Reactions in Hospitalization Reports
Top reactions in 27,509 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DYSPNOEA | 2,426 |
| ATRIAL FIBRILLATION | 1,760 |
| ANAEMIA | 1,600 |
| FALL | 1,576 |
| ACUTE KIDNEY INJURY | 1,394 |
| OFF LABEL USE | 1,338 |
| FATIGUE | 1,167 |
| DIZZINESS | 1,098 |
| GASTROINTESTINAL HAEMORRHAGE | 1,048 |
| PNEUMONIA | 1,047 |
| HYPOTENSION | 1,042 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 1,021 |
| DIARRHOEA | 1,019 |
| CONDITION AGGRAVATED | 912 |
| NAUSEA | 904 |
| DRUG INEFFECTIVE | 837 |
| CARDIAC FAILURE | 818 |
| DRUG INTERACTION | 801 |
| PYREXIA | 800 |
| VOMITING | 778 |
Nearby — Related Medications
What the FAERS Data Reveals About apixaban Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 62,650 voluntary reports linked to apixaban and its brand equivalents (Eliquis), spanning 2005 through 2025. Of those, 6,759 (10.8%) listed death as an outcome and 27,509 (43.9%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 47% were female and 53% male; age distribution skews toward 75+, with 21,179 reports in that bracket. The single most reported reaction is atrial fibrillation with 3,970 submissions, followed by dyspnoea and cerebrovascular accident.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.